시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 에어로졸 약물전달 기기 시장 보고서(2025년)
Aerosol Drug Delivery Devices Global Market Report 2025
상품코드 : 1810822
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,294,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,098,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,902,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

에어로졸 약물전달 기기 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.4%로 594억 5,000만 달러로 성장할 것입니다. 예측 기간 동안의 성장 전망은 만성 호흡기질환의 세계 부담 증가, 디지털 및 스마트 흡입기 기술 채택 확대, 약물 및 기기 결합 혁신에 대한 투자 증가, 신흥 시장의 급속한 도시화와 오염 악화, 원격의료 및 원격 환자 모니터링의 확대에 의해 이루어질 것으로 예상됩니다. 원격의료 및 원격 환자 모니터링의 확대. 예상되는 주요 트렌드에는 순응도 추적 기능이 내장된 커넥티드 흡입기의 등장, 건조 분말 흡입기(DPI) 사용 증가, 무추진제 에어로졸 시스템 또는 친환경 에어로졸 시스템 개발, 가정용 및 여행용 분무기의 소형화 및 휴대성 향상, AI 및 모바일 사용 모니터링, 맞춤형 에어로졸 요법으로의 전환 등이 있습니다. 사용량 모니터링을 위한 AI 및 모바일 애플리케이션의 통합, 맞춤형 에어로졸 요법으로의 전환 등이 있습니다.

호흡기질환의 유병률 증가는 향후 몇 년 동안 에어로졸 약물전달 기기 시장의 성장을 촉진할 것으로 예상됩니다. 호흡기질환에는 폐와 호흡기에 영향을 미쳐 정상적인 호흡을 어렵게 하는 다양한 질환이 포함됩니다. 미세먼지, 이산화질소(NO2), 오존(O3) 등의 오염물질이 호흡기를 자극해 천식, 기관지염, 만성폐쇄성폐질환(COPD) 등 만성질환의 원인이 되기 때문입니다. 에어로졸 약물전달 기기는 약물을 폐에 직접 전달하여 호흡기질환의 치료를 돕는 것으로, 표적화된 비침습적 투여를 통해 치료 효과의 신속화, 치료 효과의 향상, 전신 부작용 감소, 환자의 순응도 향상을 가능하게 합니다. 예를 들어, 2023년 11월 호주에 기반을 둔 비영리 단체인 National Asthma Council은 2022년 한 해 동안 호주에서 천식 관련 사망자 수를 467명(여성 299명, 남성 168명)으로 보고했으며, 이는 2021년 사망자 수 355명에서 증가한 수치입니다. 그 결과, 호흡기질환의 유병률 증가는 에어로졸 약물전달 기기 시장 확대에 박차를 가하고 있습니다.

에어로졸 약물전달 기기 시장의 주요 기업들은 약물전달의 정확도를 높이고 비강 커버리지를 높이며 환자의 편안함을 높이기 위해 스프레이 노즐 팁 기술과 같은 혁신적인 기술에 초점을 맞추고 있습니다. 스프레이 노즐 팁 기술은 약물전달을 위한 미세하고 균일한 에어로졸 미스트를 생성하는 미세 가공 부품으로 구성되어 있습니다. 예를 들어, 2024년 10월 독일 제조업체인 Aero Pump GmbH는 네덜란드 제약회사 Resyca B.V.와 공동으로 Ultra Soft Nasal Pump Spray를 출시했습니다. 이 장치는 스프레이 노즐 팁 기술을 이용하여 미세하고 일관된 소프트 미스트를 발생시켜 비강에서 뇌로 가는 치료나 비강을 통한 백신 접종 등의 치료에서 전달 정확도, 비강 커버리지, 사용자의 편안함을 향상시킵니다. 혁신적인 스프레이 노즐 팁은 천천히 움직이는 에어로졸 입자를 생성하여 비강의 더 깊은 부위에 도달할 수 있는 에어로졸 입자를 생성하여 후각 영역과 같이 도달하기 어려운 부위에서 약물 흡수를 개선합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Aerosol drug delivery devices are medical instruments designed to administer medications as a fine mist or tiny particles for inhalation. These devices enable targeted delivery to the respiratory system, improving drug absorption and treatment effectiveness. They are specifically engineered to optimize particle size and airflow for efficient pulmonary delivery.

The primary product categories of aerosol drug delivery devices include metered dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, smart inhalers, and other types. Metered dose inhalers are portable, handheld tools that deliver accurate doses of medication as an aerosol mist, providing rapid relief for respiratory conditions. These devices comprise various parts such as delivery mechanisms, compressor units, medication reservoirs, accessories, and consumables. They are applied in treating conditions like asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, non-respiratory diseases, diabetes, pain management, and Parkinson's disease. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, serving end users such as hospitals, homecare environments, pharmaceutical firms, research organizations, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The aerosol drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides aerosol drug delivery devices market statistics, including the aerosol drug delivery devices industry global market size, regional shares, competitors with the aerosol drug delivery devices market share, detailed aerosol drug delivery devices market segments, market trends, and opportunities, and any further data you may need to thrive in the aerosol drug delivery devices industry. This aerosol drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The aerosol drug delivery devices market size has grown strongly in recent years. It will grow from $37.92 billion in 2024 to $41.55 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth during the historic period was driven by an increasing prevalence of respiratory diseases, a growing global elderly population, heightened public awareness about air quality, rising demand for home healthcare, better availability of generic inhalation therapies, and supportive reimbursement policies in developed regions.

The aerosol drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $59.45 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The projected growth during the forecast period is driven by the increasing global burden of chronic respiratory diseases, greater adoption of digital and smart inhaler technologies, rising investments in drug-device combination innovations, rapid urbanization and worsening pollution in emerging markets, and the expansion of telemedicine and remote patient monitoring. Key trends expected include the emergence of connected inhalers with built-in adherence tracking, increased use of dry powder inhalers (DPIs), development of propellant-free or environmentally friendly aerosol systems, miniaturization and enhanced portability of nebulizers for home and travel use, integration of AI and mobile applications for usage monitoring, and a move toward personalized aerosol therapies.

The rising prevalence of respiratory diseases is expected to drive the growth of the aerosol drug delivery devices market in the coming years. Respiratory diseases encompass a range of medical conditions affecting the lungs and respiratory system, making normal breathing difficult. This increase in respiratory diseases is mainly attributed to rising air pollution levels, as pollutants like particulate matter, nitrogen dioxide (NO2), and ozone (O3) irritate the respiratory tract and contribute to chronic illnesses such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD). Aerosol drug delivery devices aid in treating respiratory diseases by delivering medication directly to the lungs, which allows for faster therapeutic effects, improved treatment efficacy, reduced systemic side effects, and better patient adherence through targeted, non-invasive administration. For example, in November 2023, the National Asthma Council, an Australia-based non-profit organization, reported 467 asthma-related deaths in Australia during 2022, including 299 females and 168 males, up from 355 deaths in 2021. Consequently, the growing prevalence of respiratory diseases is fueling the expansion of the aerosol drug delivery devices market.

Leading companies in the aerosol drug delivery devices market are focusing on innovative technologies such as spray nozzle chip technology to improve drug delivery accuracy, enhance nasal cavity coverage, and increase patient comfort. Spray nozzle chip technology consists of a micro-engineered component that produces a fine, uniform aerosol mist for medication delivery. For instance, in October 2024, Aero Pump GmbH, a Germany-based manufacturer, collaborated with Resyca B.V., a pharmaceutical company from the Netherlands, to introduce the Ultra Soft Nasal Pump Spray. This device utilizes spray nozzle chip technology to generate a fine and consistent soft mist, enhancing delivery precision, nasal cavity coverage, and user comfort for treatments like nose-to-brain therapies and nasal vaccinations. The innovative spray nozzle chip creates slow-moving aerosol particles capable of reaching deeper parts of the nasal passage, improving drug absorption in difficult-to-reach areas such as the olfactory zone.

In January 2025, Molex LLC, a US-based electronics and connectivity solutions provider, acquired Vectura Group Limited from Vectura Fertin Pharma Ltd. for an undisclosed amount. This acquisition aims to expand Molex's inhalation drug delivery capabilities, strengthen its end-to-end pharmaceutical development services, and broaden its portfolio in combination product development. Vectura Group is a UK-based pharmaceutical company specializing in dry powder inhalers, metered dose inhalers, nasal inhalers, and nebulizers.

Major players in the aerosol drug delivery devices market are Merck & Co. Inc., Novartis AG, AstraZeneca PLC, GSK PLC, Boehringer Ingelheim Pharma GmbH & Co. KG, Medline Industries LP, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Omron Healthcare Inc., AptarGroup Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Gerresheimer AG, Drive DeVilbiss Healthcare LLC, Beximco Pharmaceuticals Limited, Sensirion AG, Aerogen Limited, PARI GmbH, Pneuma Respiratory Inc., and Iconovo AB.

North America was the largest region in the aerosol drug delivery devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in aerosol drug delivery devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the aerosol drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The aerosol drug delivery devices market consists of sales of breath-actuated inhalers, vibrating mesh nebulizers, ultrasonic nebulizers, smart inhalers, and valved holding chambers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Aerosol Drug Delivery Devices Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on aerosol drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for aerosol drug delivery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The aerosol drug delivery devices market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Aerosol Drug Delivery Devices Market Characteristics

3. Aerosol Drug Delivery Devices Market Trends And Strategies

4. Aerosol Drug Delivery Devices Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Aerosol Drug Delivery Devices Growth Analysis And Strategic Analysis Framework

6. Aerosol Drug Delivery Devices Market Segmentation

7. Aerosol Drug Delivery Devices Market Regional And Country Analysis

8. Asia-Pacific Aerosol Drug Delivery Devices Market

9. China Aerosol Drug Delivery Devices Market

10. India Aerosol Drug Delivery Devices Market

11. Japan Aerosol Drug Delivery Devices Market

12. Australia Aerosol Drug Delivery Devices Market

13. Indonesia Aerosol Drug Delivery Devices Market

14. South Korea Aerosol Drug Delivery Devices Market

15. Western Europe Aerosol Drug Delivery Devices Market

16. UK Aerosol Drug Delivery Devices Market

17. Germany Aerosol Drug Delivery Devices Market

18. France Aerosol Drug Delivery Devices Market

19. Italy Aerosol Drug Delivery Devices Market

20. Spain Aerosol Drug Delivery Devices Market

21. Eastern Europe Aerosol Drug Delivery Devices Market

22. Russia Aerosol Drug Delivery Devices Market

23. North America Aerosol Drug Delivery Devices Market

24. USA Aerosol Drug Delivery Devices Market

25. Canada Aerosol Drug Delivery Devices Market

26. South America Aerosol Drug Delivery Devices Market

27. Brazil Aerosol Drug Delivery Devices Market

28. Middle East Aerosol Drug Delivery Devices Market

29. Africa Aerosol Drug Delivery Devices Market

30. Aerosol Drug Delivery Devices Market Competitive Landscape And Company Profiles

31. Aerosol Drug Delivery Devices Market Other Major And Innovative Companies

32. Global Aerosol Drug Delivery Devices Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Aerosol Drug Delivery Devices Market

34. Recent Developments In The Aerosol Drug Delivery Devices Market

35. Aerosol Drug Delivery Devices Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기